Maxvax Biotechnology Co., Ltd. (“the Company”), founded in 2016, is a global biopharmaceutical company dedicated to the research, development, manufacturing, and commercialization of innovative vaccines and novel adjuvants. The Company has been recognized as a National High-Tech Enterprise and a “Specialized, Refined, Distinctive, and Innovative” SME in Sichuan Province, and has been consecutively listed among GEI China’s (Potential) Unicorn Companies.

Founded by internationally renowned vaccine expert Dr. Dexiang Chen, the Company’s executive team includes senior professionals who previously worked for leading domestic and international vaccine companies as well as global public health organizations. This outstanding management team brings both a world-class vision for vaccine innovation and extensive industrialization experience.

Over nearly a decade of development, the Company has established internationally leading platforms for novel adjuvants, recombinant proteins, and immunological evaluation. It has developed nearly 20 adjuvant raw materials, built three mature delivery system categories, and created more than 10 composite formulations, forming a fully integrated innovative adjuvant industry chain spanning raw material R&D and production to finished adjuvant formulations.

Leveraging its core technology platforms, the Company has built a diversified product pipeline, with three candidates currently in clinical trials. To further accelerate the industrialization of novel adjuvants and human vaccines, the Company has established an innovative vaccine technology transfer platform and is currently constructing its manufacturing base.

Driven by strong and sustained business growth, the Company has completed its Series D financing, with cumulative funding exceeding RMB 2 billion.

Guided by its core values of “Integrity First, Innovation for Excellence, Boundless Collaboration, and Global Service,” the Company is committed to addressing global public health challenges and providing solutions for the prevention and control of major diseases and infectious diseases. Focused on novel adjuvants, the Company strives to break barriers in China’s innovative vaccine development while delivering high-quality, China-developed vaccines to the world.